Pemetrexed-induced severe rhabdomyolysis in lung cancer: A case report.

Kevin SullivanChung-Shien Lee

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2018)

Pemetrexed is an antifolate metabolite used to treat non-small cell lung cancer in the adjuvant and advanced setting. It is commonly known to cause rash, diarrhea, fatigue, mucositis, and myelosuppression. We report a case of a patient receiving adjuvant cisplatin and pemetrexed for non-small cell lung adenocarcinoma and experienced severe rhabdomyolysis.

Keyphrases

small cell lung cancer
advanced non small cell lung cancer
acute kidney injury
early stage
drug induced
early onset
high glucose
single cell
case report
radiation induced
cell therapy
diabetic rats
mesenchymal stem cells
endothelial cells
clostridium difficile
bone marrow